August 27, 2021

**Lilly's statement on the reopening of distribution for COVID-19 antibody therapies in the U.S.**

Today, the Office of the Assistant Secretary for Preparedness and Response (ASPR), alongside the U.S. Food and Drug Administration (FDA), has resumed the shipment and distribution of bamlanivimab and etesevimab administered together. Direct ordering will be available to authorized states effective immediately.

The decision to resume distribution aligns with FDA's issuance of an updated Fact Sheet and revised Letter of Authorization for bamlanivimab and etesevimab together. These include a revised limitation of authorized use, only allowing use in states, territories, and US jurisdictions with a low prevalence of variants that are resistant to treatment with the antibodies.

The Delta (B.1.617.2/AY.3) variant currently accounts for nearly 96 percent of all identified COVID-19 cases in the U.S. As shown in revisions to Section 15 (Microbiology/ Resistance) of the HCP Fact Sheet, pseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retained neutralization activity against the Alpha and Delta variants. As other authorized monoclonal antibody therapies are available, we advise healthcare providers to choose an authorized option with activity against the circulating variants in their region.

As we have seen over the last several months, prevalence of variants varies by state, region and even country and can change rapidly. As variants continue to evolve and their patterns of transmission and prevalence shift, we will continue our work with governments and regulators worldwide to ensure our antibodies are available to appropriate patients.

For more information, click **here** or call the Lilly COVID Hotline at **1-855-545-5921**.

###